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Abstract: Glioblastoma (GBM) is the most prevalent malignant primary brain tumor with a very poor
survival rate. Temozolomide (TMZ) is the common chemotherapeutic agent used for GBM treatment.
We recently demonstrated that simvastatin (Simva) increases TMZ-induced apoptosis via the inhibition
of autophagic flux in GBM cells. Considering the role of the unfolded protein response (UPR) pathway
in the regulation of autophagy, we investigated the involvement of UPR in Simva–TMZ-induced
cell death by utilizing highly selective IRE1 RNase activity inhibitor MKC8866, PERK inhibitor
GSK-2606414 (PERKi), and eIF2α inhibitor salubrinal. Simva–TMZ treatment decreased the viability
of GBM cells and significantly increased apoptotic cell death when compared to TMZ or Simva alone.
Simva–TMZ induced both UPR, as determined by an increase in GRP78, XBP splicing, eukaryote
initiation factor 2α (eIF2α) phosphorylation, and inhibited autophagic flux (accumulation of LC3β-II
and inhibition of p62 degradation). IRE1 RNase inhibition did not affect Simva–TMZ-induced cell
death, but it significantly induced p62 degradation and increased the microtubule-associated proteins
light chain 3 (LC3)β-II/LC3β-I ratio in U87 cells, while salubrinal did not affect the Simva–TMZ
induced cytotoxicity of GBM cells. In contrast, protein kinase RNA-like endoplasmic reticulum kinase
(PERK) inhibition significantly increased Simva–TMZ-induced cell death in U87 cells. Interestingly,
whereas PERK inhibition induced p62 accumulation in both GBM cell lines, it differentially affected
the LC3β-II/LC3β-I ratio in U87 (decrease) and U251 (increase) cells. Simvastatin sensitizes GBM
cells to TMZ-induced cell death via a mechanism that involves autophagy and UPR pathways.
More specifically, our results imply that the IRE1 and PERK signaling arms of the UPR regulate
Simva–TMZ-mediated autophagy flux inhibition in U251 and U87 GBM cells.
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1. Introduction
Glioblastoma multiforme (GBM) is the most common malignant tumor of the central nervous
system (CNS) [1–3]. The tumor is invasive and incurable with poor prognosis and inevitable
recurrences [4,5]. The average survival of GBM patients is about 15 months [6,7]. GBM therapy
comprises surgery, temozolomide (TMZ), radiochemotherapy, and TMZ maintenance chemotherapy [8].
TMZ is administered orally and induces apoptotic cell death due to DNA damage [9].
Statins are FDA-approved mevalonate (MEV) cascade inhibitors that directly inhibit
3-hydroxy-3-methyl-glutaryl–CoA (HMG–CoA) reductase [10,11]. They reduce cholesterol synthesis
by interfering with the signaling pathways involved in tumorigenesis including intermediates that are
involved in the prenylation small Rho GTPases [12]. Epidemiological studies have shown that the
long-term consumption of statins reduces mortality rates of different types of cancer, including GBM
(it is worth mentioning that in GBM, it reduces the mortality but is not statistically significant) [13,14].
In addition, preclinical studies have confirmed the anticancer, anti-proliferative, and anti-metastatic
properties of statins in several cancers such as myeloma, leukemia, glioma, breast, and prostate
cancer [15–17].
Autophagy, apoptosis, and the unfolded protein response (UPR) play critical roles in determining
the fate of cancer cells before and after chemotherapy [18,19]. These mechanisms play an important
role in the regulation of TMZ chemo-resistance in GBM [20–22]. GBM tumor progression is associated
with increased endoplasmic reticulum (ER) stress due to the high demand for protein folding and
intercellular transport of newly synthesized proteins [23]. Tumor cells utilize several signaling pathways
to restore cellular homeostasis or respond to chemotherapy induced-stress, including macroautophagy
(hereafter autophagy), UPR, ER-associated protein degradation (ERAD), and apoptosis [20].
Autophagy degrades damaged organelles and allows misfolded proteins to be recycled in
response to cellular stress and starvation, thereby suppressing tumor development in the early
stages of cancers, whereas it improves tumor progression at advanced stages of tumor development
via inducing resistance to chemotherapeutic agents [24–28]. The UPR is also activated in response
to the accumulation of unfolded proteins in the ER [29]. The UPR is orchestrated by three ER
transmembrane proteins, activated transcription factor 6 (ATF6), protein kinase RNA-like ER
kinase (PERK), and serine/threonine-protein kinase/endoribonuclease inositol-requiring enzyme
1α (IRE1α) [23,30]. Upon activation, UPR signaling may result in cell adaptation to stress or cell death,
depending on cell type, nature of the stress stimulus, and duration and severity of cell stress [21,31].
The UPR has emerged as a therapeutic target for the treatment of cancer, as this pathway is over-activated
in cancer in comparison to healthy, non-proliferative cells [32]. UPR is also involved in the shaping of
tumor microenvironment through an IRE1α-dependent alteration of the tumor cells secretome [33].
As such, targeting IRE1α could serve as a potential therapeutic option in cancers.
We recently reported a close link between autophagy and UPR [34–37]. Others have also reported
crosstalk between autophagy and UPR in different in vitro and in vivo models. Activation of the IRE1
arm regulates autophagy by modulating Beclin-1 protein expression [38,39], whereas PERK induces the
expression of several proteins belonging to the autophagy-related genes (ATG) family, including ATG
3, 5, 7, 10, and 12 [20].
We have recently demonstrated that Simvastatin (Simva) increases TMZ-induced apoptosis via
targeting autophagosome/lysosome fusion in both GBM cell lines and primary GBM patient-derived
cells [40,41]. Considering the role of the UPR pathway in the regulation of autophagy and cell death
pathways [27,36,37,42], our hypothesis was to investigate how UPR is involved in the regulation of
Simva–TMZ combination therapy cell death in GBM cells. For this purpose, we evaluated the effects of
Simva–TMZ on the UPR arms (IRE-1α and PERK) in GBM cells, using highly selective IRE-1α and
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PERK inhibitors. We later assessed how these inhibitors were involved in the regulation of Simva–TMZ
effects on autophagy flux and cell death in GBM cells.
2. Results
2.1. Co-Treatment with Simva-TMZ Increases Mevalonate Caspase Independet Cytotoxicity and Autophagy
Flux Inhibtion in GBM Cells
In our previous investigations, we have shown that Simva–TMZ combination treatment
significantly reduced cell viability in U87 and U251 as compared with Simva and TMZ alone [41].
Briefly, we treated GBM cells (U87 and U251) with TMZ (100 µM), Simva (1 µM for U251 and 2.5 µM
for U87), and mevalonate (2.5 mM) at the 72 h time-point for all of our treatments. We chose these
concentrations based on the initial screening of the cell viability experiments for different concentrations
of these compounds on GBM cells (Figure S1A–F). We selected Simva and the TMZ concentrations in
each cell line based on their cell viability in 72 h (70% < cell viability < 95%), so the single treatment
has toxicity less than 30%. We also selected mevalonate concentration based on its inhibitory effect on
mevalonate cascade and the lowest cytotoxic effects on GBM cells, as previously established by our
team [40,41,43].
Later, we further confirmed that Simva–TMZ co-treatment significantly reduced cell viability in
U87 and U251 as compared with Simva (p < 0.05 and p < 0.0001, respectively) and TMZ alone (p < 0.01
and p < 0.0001, respectively) (Figure S2A,B). Furthermore, co-treatment with mevalonate did not have
any significant effects on the loss of cell viability induced by Simva–TMZ (Figure S2A,B).
We further confirmed that co-treatment with Simva and TMZ induced significant apoptosis in
U87 and U251 cells (22.6% and 34.3%, p < 0.00001) compared with TMZ (7.74% and 21.5%) and Simva
alone (15.7% and 29%) at 72 h, as determined by changes in the sub-G1 DNA content of the cells
(Figure S3A–C). Our observations showed that TMZ single treatment induced significantly lower
apoptosis compared to Simva. Single treatment in both cell lines reflects the different apoptosis
mechanisms of these compounds [40,41]. In both cell lines, mevalonate (2.5 mM) prevented apoptosis
induced by Simva alone and partially inhibited Simva–TMZ-induced apoptosis. It is worth mentioning
that the inhibitory effect of mevalonate on Simva–TMZ-induced apoptosis was far more pronounced
in U87 than in U251 cells. These findings suggest that Simva–TMZ-induced apoptosis is partially
dependent on mevalonate cascade.
We also assessed the protein amount of the autophagy markers, Beclin-1, p62,
and microtubule-associated proteins light chain 3 (LC3β)-II in U87 and U251 treated cells at 72 h
(Figure S4). Co-treatment with Simva and TMZ increased Beclin-1 protein amount and induced the
accumulation of p62 and lipidated LC3β-II compared to the time-matched control. Autophagy flux
refers to the flow of the autophagosome to lysosomes for degradation and usually is detected using
LC3-β lipidation and the degradation of p62 [44]. These findings confirm our recent findings that
Simva–TMZ inhibits autophagic flux in GBM cells [41].
2.2. Co-Treatment with Simva–TMZ Induces UPR in GBM Cells
We also studied the protein amount of GRP78, IRE1, XBP1s, ATF6, eIF2α, and phospho-eIF2α
(p-eIF2α) proteins, which are key markers of the UPR pathway in the GBM cell models upon treatment
with TMZ, Simva, and Simva-TMZ, after 72 h. We also used dithiothreitol (DTT, 10 mM) as a
positive control for UPR induction. We also used time zero control for all experiments to evaluate
the status of UPR at the beginning of the treatments. In both cell lines, Simva–TMZ significantly
increased GRP78, IRE1, XBP-1s, and ATF-6 protein amount compared to treatment with Simva or
TMZ alone. Simva–TMZ co-treatment significantly increased the p-eIF2α/eIF2α ratio in U87, while it
decreased in U251 compared to Simva and TMZ single treatment (Figure 1, Figures S5A–E and S6A–E).
In addition, Simva–TMZ significantly induced caspase-3 cleavage in parallel to UPR induction in both
cell lines (Figures S5F and S6F). It is worth mentioning that some proteins (e.g., ATF6) showed different
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immunoblotting patterns possibly due to various isoforms or a possible phosphorylated site between
U87 and U251 cells.
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Figure 1. Simvastatin–temozolomide (Simva–TMZ) treatment induces unfolded protein response (UPR)
concomitant with cell death and DNA damage in GBM cells. U87 and U251 cells were treated with TMZ,
Simva, and Simva–TMZ for 72 h as described in the material and methods section. Cells were collected
and lysed. The expression of protein markers of UPR (GRP-78, IRE-1, XBP-1s, ATF6, eIF2α, and p-eIF2α)
was determined by immunoblotting. glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used
as the loading control. Simva–TMZ increased the protein amount of GRP-78, IRE-1, and XBP-1s, and it
decreased the ratio of p-eIF2α/eIF2α as compared to the time-matched control. Immunoblots are
representative of three different biological replicates.
2.3. IRE-1α RNase Inhibition Does Not Impact the Effects of Simva, TMZ, or Simva–TMZ on Cell Viability of
GBM Cells
We treated GBM cells with different doses of the selective IRE-1α RNase inhibitor,
MKC8866 (10–80 µM) for 48 and 72 h (Figure 2A,B). MKC8866 decreased the viability of U251
and U87 cells (80 µM, p < 0.0001 and 30 µM, p < 0.001, respectively) at 72 h compared to the
time-matched control. In addition, our results showed that MKC8866 (30 µM) inhibited IRE1-1α
RNase activity as determined by a decrease in XBP-1s protein levels upon treatment with Simva–TMZ
(Figure 3A–C) and by qPCR upon treatment with Simva or Simva–TMZ (Figure 3D,E) in both cell lines.
The treatment of cells with either Simva or TMZ alone moderately reduced XBP-1 mRNA expression in
U87 cells, which was further reduced for Simva but normalized to control levels for TMZ by MKC8866.
Next, we evaluated if the IRE-1/XBP-1 axis is involved in the Simva-mediated sensitization of GBM
cells t TMZ-induced cell death at 72 h to correlate investigate the possible regulation of autophagy
flux via IRE-1/XBP-1. W inh bited IRE-1 RNase activity using MKC8866 (30 µM) and treated U87
and U251 cells with Simva, TMZ, or Simva–TMZ for 72 h. As shown in Figure 2C,D, IRE-1α RNase
inhibition did not affect Simva-, TMZ-, or Simva–TMZ-induced c ll death in either cell l ne. As shown
in Fig r 2E,F, IRE-1α RNase inhibition did not affect Simva-, TMZ-, or Simva–TMZ-induced apoptosis
in either cell line.
Cells 2020, 9, 2339 5 of 24
Cells 2020, 9, x FOR PEER REVIEW 5 of 24 
 
Figure 2. Inositol-requiring enzyme 1 (IRE1α) RNase inhibition does not affect Simva–TMZ-induced 
cell death. (A,B) U87 and U251 cells were treated with different concentrations of MKC8866 (IRE-1α 
RNAse inhibitor; 10, 20, 30, 40, and 80 µM) for 48 and 72 h, and cell viability was evaluated by 3-(4,5-
dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (MTT) assay. Control cells were treated 
with the solvent (DMSO) for each time point. MKC8866 significantly reduced cell viability in U87 (30 
µM; 48 h, p < 0.05, 72 h, p < 0.001), (40 µM; 48 h, p < 0.05, 72 h, p < 0.0001), (80 µM; 48 h, p < 0.001, 72 h, 
p < 0.0001) and U251 (80 µM; 48 h, p < 0.05, 72 h, p < 0.0001) cells. (C,D) U87 and U251 cells were 
pretreated with MKC8866 (30 µM) for 4 h and subsequently co-treated with TMZ, Simva, or Simva–
TMZ for 72 h. Cell viability was measured by MTT assay. MKC8866 did not significantly change 
Simva-, TMZ-, or Simva–TMZ-induced cell death in glioblastoma (GBM) cells. (E,F) U87 and U251 
cells were pretreated with MKC8866 (30 µM) for 4 h and subsequently co-treated with TMZ, Simva, 
or Simva–TMZ for 72 h. Apoptosis was measured by Nicoletti assay. MKC8866 did not significantly 
change Simva-, TMZ-, or Simva-TMZ-induced apoptosis in GBM cells. Findings are expressed as the 
mean ± SD of three independent experiments for MTT assay (15 replicates) and three independent 
replicates for Nicoletti assay **** p < 0.0001). NS; not significant 
Figure 2. Inositol-requiring enzyme 1 (IRE1α) RNase inhibition does not affect Simva–TMZ-induced
cell death. (A,B) U87 and U251 cells were treated with different concentrations of MKC 8 6 (IRE-1α
RNAse inhibitor; 10, 20, 30, 40, and 80 µM) for 48 and 72 h, and cell viability was valuated by
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) (MTT) assay. Control cells were
treated with the solvent (DMSO) for each time point. MKC8866 significantly reduced cell viability
in U87 (30 µM; 48 h, p < 0.05, 72 h, p < 0.001), (40 µM; 48 h, p < 0.05, 72 h, p < 0.0001), (80 µM; 48 h,
p < 0.001, 72 h, p < 0.0001) and U251 (80 µM; 48 h, p < 0.05, 72 h, p < 0.0001) cells. (C,D) U87 and U251
cells were pretreated with MKC8866 (30 µM) for 4 h and subsequently co-treated with TMZ, Simva,
or Simva–TMZ for 72 h. Cell viability was measured by MTT assay. MKC8866 did not significantly
change Simva-, TMZ-, or Simva–TMZ-induced cell death in glioblastoma (GBM) cells. (E,F) U87 and
U251 cells were pretreated with MKC8866 (30 µM) for 4 h and subsequently co-treated with TMZ, Simva,
or Simva–TMZ for 72 h. Apoptosis was measured by Nicoletti assay. MKC8866 did not significantly
change Simva-, TMZ-, or Simva-TMZ-induced apoptosis in GBM cells. Findings are expressed as the
mean ± SD of three independent experiments for MTT assay (15 replicates) and three independent
replicates for Nicoletti assay **** p < 0.0001). NS; not significant.
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Figure 3. Simva–TMZ treatment induces IRE1 activation in GBM cells. (A) U87 and U251 cells were
pretreated with MKC8866 (30 µM, 4 h), followed by co-treatment with TMZ, Simva, or Simva–TMZ
for 72 h. XBP-1s protein levels were determined by Western blot analysis; GAPDH was used as the
loading control. Simva–TMZ induced XBP-1 splicing in GBM cells, which was inhibited by MKC8866.
(B,C) Densitometric analysis of the Western blot bands confirmed that Simva–TMZ significantly
(p < 0.0001) induced XBP-splicing in an IRE1α-dependent manner. (D,E). U87 and U251 cells were
pretreated with MKC8866 (30 µM, 4 h) and then co-treated with TMZ, Simva, or Simva–TMZ for 72 h,
after which and XBP-1s mRNA expression was measured by real-time PCR. In line with the effects
on protein amount, Simva–TMZ significantly (p < 0.0001) induced XBP splicing, which was inhibited
by MKC8866. The data are expressed as the mean ± SD of three independent experiments ** p < 0.01,
*** p 0.001; **** p < 0.0001).
2.4. Inhibition of IRE-1α R ase Activity Regulates the Effect of Co-Treat ent with Si va and T Z on
Autophagic Flux Inhibition without Affecting the Overall Cytotoxic Effect
Co-treatment with Simva and TMZ reduced autophagy flux in U87 and U251 cells (as shown in
Figure S4), and MKC8866 inhibited these effects (Figure 4A–G). In particular, MKC8866 dramatically
reduced the level of Beclin-1 and p62 induced by Simva–TMZ in both cell lines (p < 0.0001, Figure 4A–G),
suggesting that degradation of the autophagosome is regulated by the IRE1–XBP1s pathway. However,
MKC8866 did not affect the Simva–TMZ-induced increase in the LC3-βII/LC3-βI ratio in U87 cells,
while it significantly increased the ratio in U251 cells in the presence of Simva. These findings
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indicate that in the presence of Simva–TMZ, IRE1-1-XBPs inhibition does not change the production of
autophagosomes in U87 cells, but it increases autophagosome formation in U251 cells. As MKC8866
did not affect Simva–TMZ-induced cell death in U87 and U251 cells, we concluded that XBP-1 splicing
is involved in the Simva–TMZ-mediated inhibition of autophagy flux, but it does not affect the cytotoxic
effects of Simva–TMZ. This means that the IRE1/XBP-1 arm is functionally insignificant in the cytotoxic
effects of Simva–TMZ in GBM cells.
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control. Densitometric analysis of the Western blot bands confirmed that Simva–TMZ significantly 
induced Beclin-1 and p62 accumulation in both U87 and U251 cells (p < 0.0001), which was markedly 
prevented in the presence of MKC8866 (B,C,E,F). In addition, MKC8866 increased the LC3β-II/LC3β-
Figure 4. Simva–TMZ modulates the autophagy machinery via the IRE-1 pathway. (A) After
pretreatment with MKC8866 (30 µM, 4 h), U87 and U251 cells were co-treated with TMZ, Simva,
or Simva–TMZ for 72 h. The protein levels of Beclin-1, p62, LC3β-II, and LCβ-I were determined
by immunoblott g. Simva–TMZ induced an inhibition of autophagy flux (accumulation of p62
and LC3β-II) in GBM cells. In Simva–TMZ-treated cells, MKC8866 increased p62 and Beclin-1
degradation, while it differentially affected the LC3β-II/LC3β-I ratio; GAPDH was used as loading
control. Densitometric analysis of the Western blot bands confirmed that Simva–TMZ significantly
induced Beclin-1 and p62 accumulation in both U87 and U251 cells (p < 0.0001), which was markedly
prevented in the presence of MKC8866 (B,C,E,F). In addition, MKC8866 increased the LC3β-II/LC3β-I
ratio in Simva–TMZ-treated U251 cells (p < 0.0001) (G), whereas it did not change LC3β-II/LC3β-I in
U87 cells (p < 0.0001) (D). The data are shown as the mean ± SD from three independent experiments
(* p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001).
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2.5. PERK Inhibition Regulates the Effect of Co-Treatment with Simva–TMZ on Autophagy Flux in U87 and
U251 Cells and Increased Simva–TMZ-Induced Cell Death in U87 Cells
With the exception of the lowest dose tested (1 µM) in U87 cells, incubation with the PERK
inhibitor GSK-2606414 (PERKi) (1–20 µM) for 72 h had significant cytotoxic effects on GBM cells
(Figure 5A,B). Based on these results, 5 µM was used for further experimentation as it is the lowest
concentration inducing a near-maximum effect on cell viability.
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Figure 5. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) inhibition further reduces cell
viability in Simva–TMZ-treated U87 cells but not in U251 cells. (A,B) GBM cells (U87 and U251) were
treated with different concentrations of PERK inhibitor GSK-2606414 (PERKi) (1, 5, 10, and 20 µM) for
48 and 72 h, after which cell viability was assessed by MTT assay. Controls were treated with the solvent
(DMSO). The PERKi induced significant cell death at all concentrations in both cell lines, except for 1 µM
in U87 cells. (C,D) U87 and U251 were pr treated with 5 µM PERKi for 30 min and then co-treated with
TMZ, Simva, and Simva–TMZ for 72 h; cell viability was measured by MTT assay. GSK-26 6414 (PERKi)
significantly increased Simva–TMZ-induced cell death in U87 cells (p < 0.0001), but was without effect
in Simva–TMZ-treated U251 cells. (E,F) U87 and U251 were pretreated with 5 µM PERKi for 30 min
and then co-treated with TMZ, Simva, and Simva–TMZ for 72 h; apoptosis was measured by Nicoletti
assay. GSEK–PERK inhibition did not significantly change Simva–TMZ-induced apoptosis in both cell
lines. Data are expressed as the means ± SD of 15 replicates from three independent experiments for
MTT assay and three independent replicates for Nicoletti assay (* p < 0.05; ** p< 0.01, *** p < 0.001,
**** p < 0.0001).
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We carried out a dose–response of PERKi (1–20 µM) for 72 h and selected 5 µM for further
experiments. We pretreated cells with PERKi (5 µM, 30 min) and then co-treated with Simva, TMZ,
and Simva–TMZ for 48 and 72 h. PERK inhibition did not change the cytotoxic effect of Simva–TMZ in
U251 cells, whereas it further reduced cell viability in Simva–TMZ-treated U87 cells (Figure 5C,D).
Our apoptosis assay showed that Simva–TMZ co-treatment with PERKi did not significantly change
Simva–TMZ-induced apoptosis (Figure 5E,F). Immunoblotting data revealed that the PERKi blocked the
basal kinase activity of PERK and suppressed eIF2α phosphorylation (p < 0.0001). Co-treatment with
Simva–TMZ by itself significantly reduced the p-eIF2α/eIF2α ratio, which was not further decreased
by the PERKi in either cell line (Figure 6A–C).
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Figure 6. PERK inhibition does not change the p-eIF2α/eIF2α ratio in Simva–TMZ-treated cells. (A) U87
and U251 were pretreated with PERKi (5 µM, 30 min) and then co-treated with Simva–TMZ for 72 h.
The protein levels of eIF2α and p-eIF2α were determined using immunoblotting; GAPDH was used as
a loading control. (B,C) Densitometric analysis of the immunoblots showed that Simva–TMZ by itself
significantly reduced the p-eIF2α/eIF2α ratio, which was not further decreased by the PERKi in either
cell line. Of note, control levels of p-eIF2α were significantly decreased by the PERKi as well. The data
are expressed as the means ± SD of three independent experiments ** p < 0.01; **** p < 0.0001).
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We also investigated the role of PERK in the Simva–TMZ-mediated inhibition of autophagy flux
in U87 and U251 cells (Figure 7). The PERKi significantly inhibited p62 degradation (p < 0.0001) in
both cell lines, while the LC3β-II/LC3β-I ratio was decreased in U87 (p < 0.0001) and increased in
U251 (p < 0.0001) cells. These findings indicate that PERKi decreased autophagosome formation
(LC3β-II/LC3β-I) in U87 cells, induced autophagosome formation (more flux inhibition) in U251 cells,
increased Simva–TMZ-induced cell death in U87 cells; thus, we conclude that the PERKi effect on
Simva–TMZ-induced cell death might be related to autophagic flux.
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Simva–TMZ. (A) U87 and U251 cells were pretreated GSK PERK inhibitor (5 µM, 30 min) and then
co-treated with Simva–TMZ as described for 72 h. The protein levels of p62, LC3β-II, and LCβ-I were
determined by immunoblotting. Simva–TMZ induced an inhibition of autophagy flux (accumulation of
p62 and LC3β-II) in GBM cells. The PERKi decreased p62 degradation (autophagosome degradation)
in both U87 and U251 cells, while it increased the LC3β-II/LC3β-I ratio in U251 cells and decreased it in
U87 cells. GAPDH was used as a loading control. (B–E) Densitometric analysis of the Western blot
bands to quantify p62 and LC3β-II/LC3β-I protein amount. Data are expressed as the mean ± SD of
three independent experiments (** p < 0.01; **** p < 0.0001).
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2.6. Phospho-eIF2α Phosphatase Inhibitor Did Not Change Simva-TMZ-Induced Cell Death in U87
and U251 Cells
Treatment of U87 and U251 cells with the phospho-eIF2α phosphatase inhibitor (salubrinal;
1–20 µM), for 48 and 72 h, had significant cytotoxicity (except for 1 and 5 µM for 48 h in U87 cells,
Figure 8A,B). Next, cells were pretreated with salubrinal (15 µM) for 30 min before treatment with
TMZ, Simva, or Simva–TMZ. There was no detectable effect of salubrinal on the cytotoxicity of any of
the co-treatments (Figure 8C,D). We also measured apoptosis, and the cytotoxic results were confirmed
(Figure 8E,F). Immunoblotting data revealed that in combination with Simva–TMZ, salubrinal increased
eIF2α phosphorylation and the p-eIF2/eIF2α ratio (p < 0.0001) in both cell lines (Figure 9A–C).
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(A,B) U87 and U251 cells were treated with different concentrations of p-eIF2α phosphatase inhibitor 
re 8. p-eIF2α phosphatase inhibitio does not affect the cytotoxicity of Simva–TMZ in GBM
cells. (A,B) U87 and U251 cells were treated with different concentrations of p-eIF2α phosphatase
inhibitor (salubrinal; 1, 5, 10, and 20 µM) for 48 and 72 h. Controls were treated with the solvent
(DMSO). Salubrinal induced significant cell death in both cell lines, except for 1 µM in U87 cells in 48 h.
(C,D) U87 and U251 cells were pretreated with salubrinal (15 µM, 30 min) and then co-treated with
Simva, TMZ, or Simva–TMZ for 72 h; cell viability was measured by MTT assay. Salubrinal had no
significant effects on Simva-, TMZ-, or Simva–TMZ-induced cell death in either cell line. (E,F) U87 and
U251 cells were pretreated with salubrinal (15 µM, 30 min) and then co-treated with Simva, TMZ,
or Simva–TMZ for 72 h; apoptosis was measured by Nicoletti assay. Salubrinal had no significant
effects on Simva-, TMZ-, or Simva–TMZ-induced apoptosis in either cell line. Data are expressed as the
means ± SD of 15 replicates from three independent experiments for MTT assay and three independent
replicates for Nicoletti assay (* p < 0.05; ** p < 0.01, *** p < 0.001, **** p < 0.0001).
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Figure 9. p-eIF2α phosphatase inhibition increases the p-eIF2α/eIF2α ratio in Simva–TMZ treated
in GBM cells. (A) U87 and U251 cells were pretreated with salubrinal (15 µM, 30 min) followed by
co-treatment with Simva–TMZ for 72 h. Cell lysates were collected, and the p-eIF2α/eIF2α protein
amount ratios were determined using immunoblotting; GAPDH was used as a loading control.
(B,C) Densitometric analysis of the Western blot bands shows that salubrinal significantly (p < 0.0001)
increased the p-eIF2α/eIF2αratio with Simva–TMZ treatment. Data are expressed as the means ± SD of
three independent experiments (** p < 0.01, **** p < 0.0001).
3. Discussion
In the present study, we showed that co-treatment of Simva with TMZ (Simva–TMZ) increased the
sensitivity of GBM cells to TMZ-induced cell death, which occurred concomitantly with UPR induction
and autophagic flux inhibition. According to our current findings, Simva–TMZ significantly decreased
cell viability in a mevalonate independent fashion and increased apoptotic cell death, which could
(only) partially be inhibited by mevalonate. Therefore, we conclude that Simva probably sensitizes
GBM cells to TMZ-induced cell death through cellular pathways independent of HMG–CoA inhibition
and the mevalonate cascade.
The results of the MTT and the apoptotic flow cytometry assays for Mev–Simva–TMZ were
not consistent. Based on MTT data, the cytotoxic effect of Simva–TMZ could not be restored by
mevalonate, while propidium iodide (PI) analysis revealed that mevalonate could partially inhibit
the effect of combined treatment. This controversy points to some limitations of the MTT method.
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First, although the tetrazolium-based MTT assay is a standard cell viability assay, reports are indicating
the interference of such components during the staining process; second, the enzymatic conversion of
formazan crystals is (merely) sensitive to metabolic rate [45–47]. Therefore, the findings of the current
study suggested that co-treatment with Simva and TMZ induced cell death through pathways partially
dependent on mevalonate cascade; however, pleiotropic mechanisms beyond the mevalonate cascade
are likely more dominantly involved in the cytotoxic effects of Simva–TMZ.
UPR is a defense mechanism against misfolded and aggregated proteins [48] and is orchestrated by
three ER membrane sensors, ATF6, PERK, and IRE-1, which become inactive by binding to GRP78 (Bip).
UPR is connected to apoptotic cell death via different intermediates, including C/EBP homologous
protein (CHOP), phorbol-12-myristate-13-acetate-induced protein 1 (NOXA), c-Jun N-terminal kinase
(JNK), and caspase-4 and caspase-12 [36,49,50]. Autophagy is also responsible for the degradation
and removal of damaged organelles and misfolded proteins [51–53]. The term autophagic flux refers
to the degradation activity of the autophagy pathway through the formation of the phagophore and
engulfment of its p62-tagged cargo inside to form autophagosomes [41,54,55]. Autophagy and UPR
pathways are similar to double-edged swords in anticancer treatment; low levels of activation are
protective, while higher levels augment cell coping mechanisms and induce cell death [20,56–58].
Previously, we showed that Simva–TMZ induced cell death in GBM cells by autophagic
flux inhibition in a cholesterol-independent manner, since the addition of mevalonate, cholesterol,
farnesyl pyrophosphate, or geranylgeranyl pyrophosphate had no significant effects [41]. In the current
study, co-treatment with Simva–TMZ induced UPR and inhibited autophagy flux in U87 and U251 cells.
It increased the GRP78, ATF-6, and IRE-1 protein amount, as well as the XBP-1s (mRNA and protein)
level, while it decreased the p-eIF2α/eIF2α ratio downstream of phospho-PERK, compared with the
time-matched controls.
It has been suggested that the UPR can be exploited in two ways to target cancer cells [22,59]:
(1) target each arm of UPR individually to induce cell death directly or (2) exacerbate the whole cascade
to make cells (more) susceptible to chemotherapies. There are some contradictory reports on the effects
of the statins on UPR. It can inhibit [60] or activate [12] UPR and ER stress, whereas other studies
report no effects at all of the statins on these pathways [61]. Evidently, it appears that statins exert
differential ER stress responses, depending on cell type and the nature, magnitude, and duration of
stress [36]. Our observation that Simva–TMZ treatment induced an increase in the protein amount
of IRE-1, ATF6, and PERK (indicative of UPR change) is in line with research in mouse macrophage
RAW264.7 cells and bone marrow-derived macrophages (BMDM), suggesting that statins (lovastatin
and fluvastatin) upregulate the canonical UPR targets GRP78, ATF6, and XBP1, but not ATF4 and
CHOP [12]. In addition, in human atrial fibroblasts, Simva increases the level of IRE-1, BiP/GRP78,
and cleavage of ATF6, phosphorylation of PERK, XBP1 splicing, and nuclear accumulation of ATF4
and ATF6 [12].
To investigate the mechanisms of cell death and determine which signaling arm(s) of the
UPR were most affected, we used pharmacological inhibitors of PERK (PERKi), IRE-1α RNase
(MKC8866), and p-eIF2α phosphatase (salubrinal). In the presence and absence of these inhibitors,
we evaluated the effects of Simva–TMZ on cell viability and the protein levels of downstream
transcription factors (XBP-1s and p-eIF2α/eIF2α ratio). Our findings revealed that Simva–TMZ induced
the IRE-1 signaling arm and increased the level of XBP-1s, while MKC8866 failed to prevent or inhibit
the cytotoxic effect of Simva–TMZ. These findings indicate that other possible mechanisms are involved
in Simva–TMZ-induced cell death in GBM cells and that although IRE-1α RNase inhibition modulates
Simva–TMZ-induced signaling, it does not affect the overall cytotoxic effects.
Confirming findings from previous studies, we showed that Simva–TMZ inhibited autophagy
flux [41,62,63]; we demonstrate here for the first time that this is dependent on the IRE1–XBP-1s axis
(as MKC-8866 inhibited the Simva–TMZ effect). To our surprise, the cytotoxic effect of Simva–TMZ
was not affected by MKC8866. In our previous work, we found that Simva–TMZ likely triggered GBM
cell death via the inhibition of autophagy flux; however, our current findings show that the prevention
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of autophagy flux inhibition using MKC8866 was not able to inhibit Simva–TMZ-induced cell death
in GBM cells. A recent study showed that Coxsackievirus B3 autophagy induction in HeLa cells is
dependent on UPR arms as an inhibition of PERK, IRE1, or ATF6 significantly decreased autophagy
induction [64]. Researchers also showed that kaempferol (a flavonoid) induced autophagy cell death
through the IRE1 pathway in gastric cancer [65]. Caffeine induces autophagy in hepatic stellate
cells via IRE1 induction, and IRE1 knockdown in these cells decreases caffeine-induced autophagy
flux [66]. Furthermore, UPR transmembrane receptors, PERK and IRE1, modulate p62 gene regulation
in HCT116 cells [67], and IRE1 is linked to autophagy regulation after tunicamycin-induced ER stress
in MCF-7 and MDA-MB-231 cell lines [68]. Interestingly, Huntington’s disease has been associated
with autophagy flux inhibition via IRE1 activation, demonstrating the role of IRE1 in the regulation of
autophagy flux in neural cells [69]. Overall, we can conclude that the regulation of autophagy (flux)
via IRE1 highly depends on stimulus and cell type. In addition, it appears that even though IRE1
regulates autophagy flux, it might not contribute to the overall functional outcome, defining it as more
of a fine-tuning mechanism. Whether this calls into question the functional contribution of autophagy
flux to cell death in GBM cells warrants further investigation.
The PERKi did not change Simva–TMZ-induced cell death in U251 cells, but it increased
Simva–TMZ cytotoxicity in U87 cells and decreased p62 degradation in both cell lines. In addition,
the PERKi increased the LC3-β-II/LC3-β-I ratio in U251 cells but decreased it in U87 cells. These findings
show that PERK differentially regulates autophagy flux in U251 and U87 cells. Although its role in
autophagosome degradation appears similar in both cell lines, its contribution to autophagosome
formation is clearly different. Our results imply that the Simva–TMZ-mediated inhibition of autophagy
flux and (subsequent) induction of cell death is connected to the PERK pathway in U87 cells but not in
U251 cells. Recently, it has been shown that apoptosis and autophagy induced by sterol regulatory
element-binding proteins are related to PERK and UPR in osteosarcoma cells [70]. Therefore, it is
possible that in U87 cells, Simva–TMZ-induced cell death is regulated via autophagy and UPR and
connected to sterol regulatory element-binding proteins. Interestingly, chemoresistance in chordoma
was shown to be related to PERK–autophagy crosstalk, and it was suggested that targeting this pathway
could potentially overcome chemoresistance in these cells [71]. Seneca valley virus infection-induced
autophagy is connected to UPR via the PERK and ATF6 arms, which shows the connection of autophagy
to UPR in different cellular stress responses [71]. ATG proteins (ATG5, ATG7, and ATG5/ATG7 together)
are involved in the regulation of autophagy, ER stress, and apoptosis through PERK signaling in
chondrocytes; PERK has emerged to act as a hub to connect these three vital signaling pathways [72].
Based on our results, the Simva–TMZ combination decreases cell viability and the p-eIF2α/eIF2α
ratio, strongly suggesting inhibition of the PERK arm. Co-treatment with PERKi could not change this
potential effect. This suggests that the cell death mechanism of Simva–TMZ might be independent of
inhibition of the PERK kinase activity at this dose and time point. Salubrinal co-treated with Simva-TMZ
in GBM cells increased the ratio of p-eIF2α/eIF2α, as is to be anticipated with a phosphatase inhibitor,
without any effects on the cell viability. It appears that although Simva–TMZ affects the e-IF2α
phosphatase activity, this pathway is not involved in Simva–TMZ-induced cell death.
U87 and U251 cells are different cell lines from point of view of p53 status. U87 is p53 wild type,
and U251 is p53 mutant. They were both sensitive to TMZ treatment [73,74]. Based on several previous
investigations, glioma cell lines that did not express a functional p53 were more sensitive to TMZ
treatment [75–77]. Our apoptotic flow cytometry results indicate that TMZ induces cell death in U87
and U251 (7.74% and 21.5%, respectively), which could relate to p53 status in these cells.
P53 regulates UPR and autophagy pathway-related proteins [26,78]. In cancer, a mutated p53
decreases autophagy and favors the proliferation of tumor cells. Accumulating evidence shows that p53
plays a dual role in the control of autophagy [79]. On one hand, nuclear p53 can induce autophagy by
trans-activating autophagy-inducing genes. On the other hand, cytoplasmic p53 may act as a repressor
of autophagy [79]. Therefore, the difference between U251 and U87 in autophagy flux inhibition via
Simva and Simva–TMZ could be correlated to the difference of p53 between these two cell lines.
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Based on several recent studies, p53 mutant cancer cells have higher levels of IRE1, and the
activation of XBP1 was induced in the absence of stress and activation and contributes to higher
malignancy and the aggressive phenotype of the tumors [80]. It addition, it has been reported that p53
is involved in the regulation of cellular homeostasis during the UPR [81]. Therefore, a difference in
UPR between U87 and U251 in the presence of Simva–TMZ treatment could be correlated to the p53
status in these cells.
As shown in the Scheme 1, Simva sensitizes GBM cells to TMZ-induced cell death via complex
mechanisms, involving both autophagy and UPR. Co-treatment increases the GRP78, IRE-1, XBP-1s,
and cleaved caspase-3 protein amount, as well as the protein amount of Beclin-1, p62, and LC3β-II,
and it decreases the p-eIF2α/eIF2α ratio. Our findings show that although Simva–TMZ activates IRE1
RNase, inhibition of this arm does not have any effect on Simva–TMZ-induced cell death. On the
other hand, Simva–TMZ-induced cell death changes the activity of the PERK–UPR arm in both U87
and U251 cells, but the inhibition of PERK only affects Simva–TMZ-induced cell death in U87 cells.
Unequivocally, our results demonstrate the existence of an intricate connection involving IRE1 and
PERK between UPR and autophagy in our in vitro GBM models. Above all, our current investigation
highlights the potential for the use of statins in combination with a chemotherapeutic agent in the
treatment of GBM. The current investigation showed that Simva–TMZ combination therapy induced
UPR response in GBM cells, but it is not involved in its cytotoxic and apoptotic effects on GBM cells.
Interestingly, our results showed that UPR inhibition inhibited the effect of Simva–TMZ on autophagy
flux inhibition, but it did not change Simva–TMZ-induced cell death and apoptosis in GBM cells.
It shows that Simva sensitizes GBM cells to TMZ-induced apoptosis via a complex mechanism beyond
simple apoptosis, autophagy, and UPR crosstalk together and potentially depends on some unknown
Simva pleiotropic effect and needs further investigations. Currently, our team has done the in vivo
flank model of GBM (using U251 cells in immune-compromised mice) and was able to show that Simva
significantly potentiates the anti-tumor effect of TMZ in a flank model. The application of statin as
potential adjuvant chemotherapy needs critical in vitro, in vivo, and clinical investigation in the future,
and we need further clinical trials to address this issue.
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PERK activation. Activation of these arms of UPR induces Simva–TMZ inhibition of autophagy flux in
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4. Materials and Methods
4.1. Reagents and Drugs
Temozolomide (CAS Number: 856 2-93-1), simvastatin (CAS Number: 7 902-63-9), mevalonate
(CAS Number: 674-26-0), propidium iodide (CAS Number: 25535-16-4), 3-(4,5-dimethyl 2-thiazo yl)
-2,5-diphenyl-2H-tetrazolium bromide) (M T) (CAS Number: 298-93-1), PERKi (PERK kinase activity
inhibitor, GSK2606414, CAS 1 37531-89-1), and salubrinal (phosphor-eIF2α phosphatase inhibitor,
CAS 30 475-63-6) w re purchased from Sigma-Aldrich Co. (Oakville ON, Canada). MKC8866
(IRE1 RNase inhibitor) was provided by MannKind company (Los Angeles, CA, USA).
Ra bit and mouse primary antibodies against human, such as p-H2A.X, GRP78, IRE-1, ATF-6,
XBP-1s, e-IF2α, P-e-IF2α, caspase-3, Beclin-1, LC3β-II, and p62 were purchased from Cell Signaling
Technology Co. (Beverly, MA, USA). GAPDH was obtained from Santa Cruz Biotechnology Inc.
(Dallas, Texas, USA) and secondary antibodies, anti-ra bit IgG (whole molecule), and anti-mouse
immunoglobulin G (IgG) (Fab specific), conjugated with a peroxidase enzyme, were purchased from
Sigma-Aldrich (Oakville, ON, Canada).
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The enhanced chemiluminescence (ECL) Western blot (high sensitivity) substrate kit (ab133406)
was acquired from Abcam (Cambridge, MA, USA). RNA extraction reagent, BIOZOL (Zhejiang, China),
the cDNA synthesis kit Thermo Fisher Scientific (Winnipeg, MB, Canada), and SYBR Green QPCR
master mix were purchased from Applied Biosystems (Waltman, MA, USA). The bicinchonic acid
(BCA) protein assay kit was obtained Thermo Fisher Scientific (Winnipeg, MB, Canada).
4.2. Cell Lines, Culture, and Treatment
We obtained the human glioblastoma cell lines, U87 (p53 wild type) and U251 (p53 mutant), from
the Bonyakhteh Company (Bonyakhteh, Tehran, Iran). We used cells in passages 3–6 for all experiments
and bought fresh and authenticated cell lines from the company after 6 passages. The cells were
cultured in Dulbecco’s Modified Eagle’s Medium high-glucose, high glutamine (DMEM) (Bio Idea,
Tehran, Iran), supplemented with 10% Fetal Bovine Serum (FBS) (Gibco™; Cat #: 16000044) and 1%
penicillin–streptomycin (Gibco, (Waltman, MA, USA), and maintained in a humidified incubator under
95% air and 5% CO2 at 37 ◦C.
4.3. MTT Assay
MTT assay was used to measure the viability of cells under different experimental conditions.
The effect of Simva (0–20 µM), TMZ (0–1000 µM), and mevalonate (0–500 mM) on GBM viability were
evaluated at different time points (24–96 h). The effect of MKC8866 (0–80 µM), PERKi (0–20 µM),
and salubrinal (0–20 µM) on GBM on cell viability were assessed at 48 and 72 h. After determining
the optimum treatment dose for mevalonate (2.5 mM), GSK-PERK (5 µM), salubrinal (15 µM),
and MKCC8866 (30 µM), we evaluated the Simva-mediated sensitization of GBM cells to TMZ-induced
cell death and the role of UPR herein. U251 and U87 cells were seeded in 96-well plates (5000 cells
per well) and treated after reaching 40% confluency. We pretreated U251 and U87 cells with Simva
(1 and 2.5 µm, respectively) for 4 h and then co-treated them with TMZ (100 µM) for 72 h. To assess
the role of mevalonate, cells were pretreated with mevalonate (2.5 mM) for 4 h before treatment with
Simva and then co-treated with TMZ for 72 h. MTT assays were performed as described previously.
Briefly, we added 20 µL MTT to each well at the predetermined time points. We removed all the
medium after 3 h and added 200 µL DMSO. Finally, after 20 min incubation, the absorbance was read
at 570 nm [37,82]
4.4. Evaluation of Cell Death by Flow Cytometry
Cell death was evaluated using the Nicoletti method [83,84]. Briefly, U251 and U87 cells were
cultured in 6-well plates in the presence of the least toxic dose of Simva (1 and 2.5 µM, respectively,
based on MTT assay results). After incubating cells with Simva for 4 h, 100 µM TMZ was added
(without changing the media), and cells were kept under these treatment conditions (Simva–TMZ)
for 72 h. We will call this the procedure for our experimental protocol (OEP). To assess the effect of
mevalonate, GBM cells were pretreated with 2.5 µM mevalonate (MEV) for 3 h before OEP. After 72 h,
the cells were detached, and pellets were re-suspended in a hypotonic PI lysis buffer (0.1% Triton
X-100, 1% sodium citrate, 0.5 mg/mL RNase A and 40 µg/mL propidium iodide) and incubated for
30 min at 37 ◦C. The apoptotic dead nuclei were defined by flow cytometry as a sub-G1 population.
All calculations were made in 10,000-event count.
4.5. Immunoblotting
The protein assay, sample preparation, and SDS-PAGE electrophoresis were performed as described
in our previous investigations [41,85–87]. Briefly, the cells were harvested and lysed with NP-40 lysis
buffer. Based on the type of protein, 10–30 µg of total protein was subjected to electrophoresis on
SDS-PAGE gels (15% for MW 60 KD and lower, and 10% for MW > 60 KD), and separated proteins
were transferred to 0.2 µm nitrocellulose membranes (Bio-Rad; #1620112). After overnight blocking
(5% fat-free milk), the membranes were incubated with primary antibodies (P-H2A (Ser 139), GRP78,
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IRE-1, ATF-6, XBP-1s, e-IF2α, p-eIF2α (Ser 51), caspase-3, Beclin-1, LC3β-II, p62, and GAPDH) overnight
at 4 ◦C. Antibodies were used in dilutions according to the manufacturer’s protocol. After incubation
with suitable secondary antibodies for 90 min at room temperature, the membranes were incubated
with enhanced chemiluminescence (ECL) reagents (Abcam, Cambridge, MA, USA) and developed
by the ChemiDocTM MP imaging system (Bio-Rad, Hercules, CA, USA). The intensity of blots was
measured by Image Lab densitometry software, and all bands were normalized to the GAPDH protein
amount to correct for marginal deviations in protein loading.
4.6. Inhibition of Specific UPR Signaling Arms (PERK & IRE1)
We used MKC8866, a PERKi, and salubrinal to investigate the role of UPR in the regulation
of Simva–TMZ-induced cell death in GBM cells. To determine the effective doses of the inhibitors,
we treated GBM cells with 1–20 µM GSK–PERK, 1–20 µM salubrinal, and 10–80 µM MKC8866 for 72 h,
and evaluated spliced XBP-1 (XBP-1s), e-IF2α, p-eIF2α by immunoblotting. After identifying inhibitor
concentration with close to the maximal effects of each inhibitor, we used these concentrations to assess
the role of UPR in the regulation of Simva–TMZ-induced cell death.
4.7. Quantitative Real-Time PCR
Total RNA was isolated from 1 × 106 cells (U87 and U251) by the BIOZOL, and RNA
was converted to cDNA by the cDNA synthesis kit based on the manufacturer’s instructions.
Quantitative real-time PCR was carried out using the SYBR Green PCR Master Mix with the following
set of primers: GAPDH (as an internal control) forward, 5′-CGACCACTTTGTCAAGCTCA-3′, reverse,
5′-AGGGGTCTACATGGCAACTG-3′, and XBP-1s forward, 5′-TGCTGAGTCCGCAGCAGGTG-3′
and reverse, 5′-GCTGGCAGGCTCTGGGGAAG-3′. The data were analyzed by 7500 Software v 2.0.1.
The relative expression level of the XBP-1s gene was calculated by the 2−44Ct formula.
4.8. Statistical Analysis
Descriptive statistics, including mean ± SD, were calculated first. Inferential statistics (i.e., one-or
two-way Analysis of Variance (ANOVA)) were determined thereafter. Finally, a Bonferroni’s post hoc
test was used to detect the statistical significance of differences (p-value < 0.05) by GraphPad Prism
software v. 6.0. All experiments were performed in at least 3 different biological replicates.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4409/9/11/2339/s1,
Figure S1: Cytotoxic effects of mevalonate (MEV), temozolomide (TMZ) and simvastatin (Simva) in GBM cells.
U87 and U251 cells were treated with different concentrations of (A,B) mevalonate (1–500 mM), (C,D) TMZ
(25–1000 M), and (E,F) Simva (1–20 M), after which cell viability was assessed by MTT assays at different time
points (24–96 h). Control samples were treated with the solvent (DMSO for Simva and TMZ or methanol for
MEV). Data are shown as mean ± SD of 15 replicates from three independent experiments (* p < 0.05; ** p < 0.01,
*** p < 0.001, **** p < 0.0001), Figure S2: Mevalonate does not prevent Simva-TMZ-induced cell death in GBM
cell lines. U87 and U251 cells were pretreated with MEV (2.5 mM, 3 h) then co-treated with Simva, TMZ,
and Simva-TMZ for 72 h. Control samples were treated with solvent (DMSO for Simva and TMZ or methanol
for MEV). MTT assaywas performed to evaluate cell viability (A,B). Simva and TMZ co-treatment significantly
decreased cell viability as compared to control, Simva and TMZ treatment alone in both cell lines. As anticipated,
MEV fully prevented the effects of Simva on cell viability, but it failed to affect Simva-TMZ-mediated cytotoxicity.
Data are shown as mean ± SD of 15 replicates from three independent experiments (* p < 0.05; ** p < 0.01,
*** p < 0.001, **** p < 0.0001), Figure S3: Mevalonate partially inhibits Simva-TMZ-induced cell death in GBM cells.
After pre-treatment with MEV (2.5 mM, 3 h), U87 and U251 cells were co-treated with Simva, TMZ, and Simva-TMZ
for 72 h. Cell Death was determined by the propidium iodide Nicoletti assay. Simva-TMZ co-treatment significantly
increased apoptosis compared to the corresponding control, Simva, and TMZ treatment alone (A). MEV almost
completely inhibited Simva-induced apoptosis and partially prevented Simva-TMZ-induced apoptosis in h GBM
cells (B,C). Data are representative of three independent experiments and presented as mean ±SD (* p < 0.05;
** p < 0.01, *** p < 0.001), Figure S4: Simva and TMZ co-treatment induces autophagy flux inhibition in GBM
cells. (A) U87 and U251 cells were treated, with Simva, TMZ, or Simva-TMZ for 72 h. Cells were edlysedand
proteins were extracted. Autophagy-related proteins (Beclin-1, p62, LC3β) were detected using immunoblotting.
Simva-TMZ co-treatment inhibited the autophagic flux (as indicated by p62 accumulation and an increase of
LC3β-II/ LC3β-I ratio) in GBM cells. (B–G) Densitometric quantification of Beclin-1, p62, and LC3β protein levels
from immunoblots in U87 and U251 cells (normalized to GAPDH as loading control). Simva-TMZ co-treatment
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decreased degradation of p62, and increased Beclin-1 expression and the LC3β-II/ LC3β-I ratio in GBM cells.
The data are shown as the mean ± SD from three independent experiments (* p < 0.05; ** p < 0.01, *** p < 0.001;
**** p < 0.0001), Figure S5: Simva-TMZ-induced UPR in U87 cells. Densitometric analysis of the immunoblot
bands of various protein markers of UPR (GRP-78, IRE-1, XBP-1s, ATF6, and p-eIF2αeIF2α ratio) in U87 cells
(normalized to GAPDH as loading control.) Simva–TMZ significantly induced UPR, apoptosis and DNA damage
in these cells (p < 0.0001). The data are shown as the mean ± SD from three independent experiments (* p < 0.05;
** p < 0.01, *** p < 0.001; **** p < 0.0001), Figure S6: Simva-TMZ-induced UPR in U251 cells. Densitometric analysis
of the immunoblot bands of various protein markers of UPR (GRP-78, IRE-1, XBP-1s, ATF6, and p-eIF2α/eIF2α
ratio) in U251 cells (normalized to GAPDH as loading control). Simva–TMZ significantly induced UPR, apoptosis
and DNA damage in these cells (p < 0.0001). The data are shown as the mean ± SD from three independent
experiments (* p < 0.05; ** p < 0.01, *** p < 0.001; **** p < 0.0001).
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AMPK AMP-activated protein kinase;
ATF4 activating transcription factor 4;
ATF-6 activated transcription factor 6;
ATG autophagy-related protein;
CHOP C/EBP homologous protein;
eIF2α eukaryote initiation factor 2α;
ER endoplasmic reticulum;
ERAD ER-associated protein degradation;
GBM glioblastoma;
GGPP geranylgeranyl pyrophosphate;
GRP78 glucose-related peptide 78 kD;
hATF human atrial fibroblasts;
HMG–CoA hydroxy-3-methyl-glutaryl–CoA;
IRE1 inositol-requiring enzyme 1α;
JNK c-Jun N-terminal kinase;
LC3 microtubule-associated proteins light chain 3;
MEV mevalonate;
MPG methylpurine DNA glycosylase;
OEP our experimental protocol;
PERK protein kinase RNA-like ER kinase;
PERKi PERK kinase activity inhibitor;
Simva simvastatin;
TMZ temozolomide;
UPR unfolded protein response;
XBP-1s x-box binding protein-1 spliced;
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